Clinical Trial Update: Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update shows completion and posted results for the fixed-dose combination VR-AD-1005 in the treatment of cholera-related acute watery dia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholera

Drugs mentioned

• VR-AD-1005

Snippet

Sponsor: Hunazine Biotech S.L. | Conditions: Cholera | Phase 2 | Status: COMPLETED | Results posted: 2026-03-12